When it comes to prostate cancer, there’s a lot of confusion and guesswork floating around—especially among men who don’t ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

We have made important advancements in treatment, but are still being overwhelmed by the number of late-stage cases ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Clinicians from Fox Chase Cancer Center at Temple University Health share their highlights from the Society of Urologic ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...